PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Dihydroxytryptamines”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1992

Improved method for the determination of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine in tissue using high-performance liquid chromatography with electrochemical detection.

A liquid chromatographic method with electrochemical detection is described for the determination of the 5-hydroxytryptamine (5-HT) neurotoxins 5,6-dihydroxytryptamine (5,6-DHT) and 5,7-dihydroxytryptamine (5,7-DHT) in rat brain tissue. This method has also been used for the determination of 5-hydroxyindoleacetic acid, homovanillic acid and 5-HT in other tissue samples. The method is based on extraction of the indoles from brain samples with perchloric acid followed by reversed-phase liquid chromatography with electrochemical detection. The detection limit is 1 ng per 100 mg of tissue. This paper describes a quick and reliable method of assaying the 5-HT neurotoxins 5,6-DHT and 5,7-DHT in brain tissue, which is improved compared to currently available assays.

5,6-Dihydroxytryptamine↗
PubMed1985

Molecular mechanism of action of 5,6-dihydroxytryptamine. Synthesis and biological evaluation of 4-methyl-, 7-methyl-, and 4,7-dimethyl-5,6-dihydroxytryptamines.

The major mechanism by which the serotonin neurotoxin 5,6-dihydroxytryptamine (5,6-DHT) expresses its neurodegenerative action may involve alkylation of biological nucleophiles by the electrophilic quinoid autoxidation products. To determine the relative importance of various sites on these autoxidation products toward alkylation we have rationally designed and synthesized 4-Me-5,6-DHT (16a), 7-Me-5,6-DHT (16b), and 4,7-Me2-5,6-DHT (16c). The indole nucleus of these analogues was constructed by the reductive cyclization of the corresponding 2, beta-dinitrostyrenes, and the aminoethyl side chain was introduced via gramine methiodides. Redox data showed that all the analogues are more readily oxidized compared to 5,6-DHT. The biological activity was evaluated in differentiated neuroblastoma N-2a cells in culture. The order of inhibitory potency, as determined by measuring the inhibition of incorporation of [3H]thymidine into DNA, was 16c much greater than 16a greater than 5,6-DHT approximately equal to 16b. The order of affinity (expressed as IC50 values in microM) for serotonergic uptake as determined by measuring their inhibition of [3H]-5-HT uptake was 5,6-DHT (4) greater than 16c (20) greater than 16a (23) greater than 16b (52). The results of these studies established that these rationally designed C-methylated analogues of 5,6-DHT are suitable probes for elucidating the molecular mechanism of action of 5,6-DHT.

5,6-Dihydroxytryptamine↗
PubMed1984

[Effect of cerebral intraventricular administration of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine on the cyclic secretion of corticosterone in the rat].

The effect of two potent neurotoxic agents for 5HT neurons, 5,6-DHT and 5,7-DHT, intraventricularly injected, has been studied on the values and rhythm of plasmatic corticosterone secretion in the male Wistar rat model, along an entire day: 4 a.m., 8 a.m., noon, 5 p.m. and midnight. The dose administered for each drug was 100 micrograms/animal in a single injection. The levels of corticosterone were determined 15 and 30 days post-injection. The effects observed for both drugs were similar at similar times: highly significant decreases in all the studied points which fall under the same line of secretion and evince an absolute inhibition of the cyclic rhythm. There are no significant differences among the values obtained with different drugs at various times. The contents of NA and 5HT significantly decrease for both drugs especially those of the 5HT on the 15th day. 30 days after the injection there is a small recovery of 5HT, but differences with control values are still significant. On the other hand the recovery of NA was almost total (near 100%). The results are discussed within the highly controversial frame of the influence of central 5HT neurons on the various types of secretion of the hypothalamic-pituitary-adrenal axis. The data obtained with this "chronic model" are confronted with those from other authors who have used drugs with transitory effect on the 5HT brain metabolism.

5,6-Dihydroxytryptamine↗
PubMed1988

Effects of 5,6-dihydroxytryptamine on the release, synthesis, and storage of serotonin: studies using rat brain synaptosomes.

5,6-Dihydroxytryptamine is a neurotoxic analogue of serotonin which can have profound cardiovascular effects within minutes of administration in vivo (Korner and Head, 1981). These effects have been attributed to 5,6-dihydroxytryptamine-induced serotonin release, although there has been no biochemical assessment of the extent to which this occurs. The present study utilized an in vitro synaptosomal assay to determine the short-term effects of 5,6-dihydroxytryptamine on endogenous serotonin release, synthesis, storage, and metabolism. 5,6-Dihydroxytryptamine produced a rapid depletion of serotonin. At lower concentrations of 5,6-dihydroxytryptamine (0.1-1 microM), this depletion was associated primarily with an increase in the levels of 5-hydroxyindoleacetic acid, the deaminated metabolite of serotonin, with small increases in the amount of serotonin release. At higher concentrations (10-100 microM), a greater proportion of the depleted serotonin was released with less metabolism occurring. When metabolism was prevented by inhibiting monoamine oxidase, the amount of serotonin which was released equalled the amount of serotonin depletion. Thus monoamine oxidase activity was important in controlling the amount of serotonin which could be released by 5,6-dihydroxytryptamine. Further studies demonstrated that an impairment in serotonin synthesis and vesicular storage could account for the rapid depletion produced by 5,6-dihydroxytryptamine. Taken together, the results indicate that 5,6-dihydroxytryptamine acts to displace serotonin from vesicular stores into the cytoplasm where it can either be deaminated by monoamine oxidase or be released. Moreover, it is hypothesized that the intraneuronal concentration of 5,6-dihydroxytryptamine is important in determining the extent of serotonin release, because it can inhibit the deamination of serotonin by monoamine oxidase.

5,6-Dihydroxytryptamine↗
PubMed1987

The guinea pig myoclonic model: behavioral supersensitivity to 5-hydroxytryptophan induced by intracisternal 5,7-dihydroxytryptamine.

To study the species difference of guinea pigs and rats in response to 5-hydroxytryptophan (5-HTP), we injected both animals intracisternally with 5,7-dihydroxytryptamine. In rats with 5,7-dihydroxytryptamine lesions, 5-HTP evoked the well described myoclonic-serotonergic syndrome. In the guinea pig, 5,7-dihydroxytryptamine lesions significantly increased the severity of myoclonic response to 5-HTP (150 mg/kg) compared to vehicle controls, resulting in lethal convulsions. Guinea pigs treated with 5,7-dihydroxytryptamine did not develop spontaneous myoclonus, or when treated with 5-HTP, other 'serotonergic behaviors' such as lateral head weaving, hindlimb abduction, and forepaw tapping. Guinea pigs tolerated intracisternal 5,7-dihydroxytryptamine less well than rats, with a higher mortality, although immediate post-injection convulsions were less severe and did not require phenobarbital prophylaxis. Staged lower doses of 5,7-dihydroxytryptamine (100-200 micrograms) were better tolerated than a single high dose of neurotoxin (400 micrograms). The regional profile of 5,7-dihydroxytryptamine lesions in the guinea pig resembled that of the rat, with maximal depletion of 5-HT in spinal cord and selected forebrain structures, and little effect in diencephalon and midbrain. Depletions in the guinea pig were less selective for 5-HT using desipramine pretreatment than in the rat. In naive guinea pigs and rats, regional content of 5-HT was similar. These data suggest that the functional integrity of serotonergic neurons is not requisite for the expression of myoclonus induced by 5-HTP in the guinea pig. 5,7-Dihydroxytryptamine lesions in the guinea pig resulted in behavioral and neurochemical similarities and differences in comparison with the rat.

5,7-Dihydroxytryptamine↗
PubMed1998

Immunohistochemical localization and quantification of glial fibrillary acidic protein and synaptosomal-associated protein (mol. wt 25000) in the ageing hippocampus following administration of 5,7-dihydroxytryptamine.

Responses to injury in the ageing hippocampus were assessed utilizing the synaptic markers glial fibrillary acidic protein and synaptosomal-associated protein (mol. wt 25,000) following administration of the neurotoxin, 5,7-dihydroxytryptamine, into the fimbria-fornix and cingulum bundle to denervate serotonergic afferent input to the dorsal hippocampus. Age-dependent alterations in hippocampal immunohistochemical localization of glial fibrillary acidic protein and synaptosomal-associated protein were evaluated in female Fischer 344 rats following serotonergic deafferentation with 5,7-dihydroxytryptamine. Across the lifespan, as indicated by measurements taken at three, 18, 21 and 29 months, marked increases in glial fibrillary acidic protein, but not synaptosomal-associated protein immunoreactivity, occurred throughout the hippocampus at 21 and 29 months compared to three and 18 months. Following three weeks pretreatment with 5,7-dihydroxytryptamine (20 microg total dose) or vehicle (0.1% ascorbic saline; 2 microl total volume) infused in the fimbria-fornix/cingulum bundle, immunohistochemical analysis demonstrated marked increases of glial fibrillary acidic protein, but not synaptosomal-associated protein, in the 18-month 5,7-dihydroxytryptamine group compared to the 18-month vehicle and 3-month 5,7-dihydroxytryptamine groups. Additionally, a significant increase in glial fibrillary acidic protein concentration was found by enzyme-linked immunosorbent assay in the 18-month 5,7-dihydroxytryptamine group compared to the 18-month vehicle and three-month 5,7-dihydroxytryptamine groups. These results demonstrate that selective neurotoxicant damage of the hippocampal serotonergic system differentially alters the expression of glial fibrillary acidic protein. This approach may provide a valuable tool to determine the ability of the hippocampus to respond to age-related neurodegenerative injury.

5,7-Dihydroxytryptamine↗
PubMed1986

Direct histochemical localisation of 5,7-dihydroxytryptamine and the uptake of serotonin by a subpopulation of GABA neurones in the rabbit retina.

The same cells in both the intact retina and retinal cultures of the rabbit retina take up exogenous serotonin or 5,7-dihydroxytryptamine. Both substances can be localised by immunohistochemistry using a monoclonal antibody directed against serotonin. The 5,7-dihydroxytryptamine can also be revealed directly in both fixed and living tissues using appropriate U.V. light. Some of the cells in the intact retina and retinal cultures which take up 5,7-dihydroxytryptamine also stain positively for the immunohistochemical localisation of gamma-aminobutyric acid (GABA). Cell counts in the cultures show that 80% of all 5,7-dihydroxytryptamine-positive cells stain positively for GABA, while 20% of the GABA-immunoreactive cells also accumulate 5,7-dihydroxytryptamine. These results demonstrate unambiguously that a subpopulation of GABA cells has the capacity to take up exogenous 5,7-dihydroxytryptamine and therefore utilise GABA and, probably, serotonin. Findings in favour of the 'co-occurrence' of GABA and serotonin come from studies where tissues were exposed to radioactive GABA and unlabelled serotonin so that the dual localisation of these substances by autoradiography and immunohistochemistry could be followed. It could be shown both in cultures and in intact retinal pieces that certain cells take up GABA and serotonin while other cells take up either GABA or serotonin.

5,7-Dihydroxytryptamine↗
PubMed1994

The induction of serotonin3-like receptor supersensitivity and dopamine receptor subsensitivity in the rat medial prefrontal cortex after the intraventricular administration of the neurotoxin 5,7-dihydroxytryptamine: a microiontophoretic study.

This study examines the effect of intraventricular administration of the neurotoxin 5,7-dihydroxytryptamine on serotonin1A, serotonin2 and serotonin3 receptors in the rat medial prefrontal cortex using in vivo extracellular single cell recording and iontophoresis. Iontophoresis of the serotonin1A, serotonin1C,2 and serotonin3 receptor agonists (+-)-8-hydroxy-(di-n-propyl)aminotetralin, (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and 2-methylserotonin, respectively, produces a current-dependent (5-80 nA) suppression of the basal firing rate of medial prefrontal cortical cells in sham- and 5,7-dihydroxytryptamine-lesioned rats. The suppression produced by 2-methylserotonin and serotonin was significantly greater in 5,7-dihydroxytryptamine-lesioned rats than in control rats. No significant difference in the spontaneous activity of medial prefrontal cortex cells was observed between experimental and control rats after iontophoresis of (+-)-8-hydroxy-(di-n-propyl)aminotetralin or (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane. There was no significant difference between the groups regarding the response of medial prefrontal cortex cells to the iontophoresis of GABA, whereas the response of medial prefrontal cortex cells to the iontophoresis of dopamine was significantly attenuated in animals pretreated with 5,7-dihydroxytryptamine compared to controls. Our results indicate that 5,7-dihydroxytryptamine-induced denervation selectively enhances the sensitivity of serotonin3-like receptors in the medial prefrontal cortex, which could, at least partially, account for the serotonin denervation supersensitivity. Moreover, the finding that the response of medial prefrontal cortical cells to the iontophoresis of dopamine is attenuated in 5,7-dihydroxytryptamine pretreated rats is consistent with the view that the inhibitory action of dopamine in the medial prefrontal cortex is dependent upon serotonin tone.

5,7-Dihydroxytryptamine↗
PubMed1973

The 5-hydroxytryptamine-like actions of 5,6-dihydroxytryptamine.

1. With isolated preparations of rat stomach fundus as well as of duodenum and ileum of rats and guinea-pigs, 5,6-dihydroxytryptamine and 5,6-diacetoxytryptamine caused a contraction which was antagonized by methysergide and lysergic acid diethylamide (LSD), but not by atropine. Pretreatment of the animals with reserpine did not decrease the effect of the two indoleamines on the isolated ileum and duodenum.2. In anaesthetized guinea-pigs, 5,6-dihydroxytryptamine and its diacetyl derivative caused bronchoconstriction which was antagonized by methysergide, but not modified by pretreating the animals with reserpine.3. In anaesthetized cats, 5,6-dihydroxytryptamine had, in general, a hypotensive effect which was reversed by hexamethonium.4. 5,6-Dihydroxytryptamine also caused aggregation of isolated rabbit and human platelets and inhibited the platelet aggregation induced by 5-hydroxytryptamine (5-HT) plus adrenaline.5. The pattern of action of 5,6-hydroxytryptamine and 5,6-diacetoxytryptamine was qualitatively the same as that of 5-HT, but the potency of the compounds decreased in the order 5-HT, 5,6-dihydroxytryptamine, 5,6-diacetoxytryptamine both in vitro and in vivo.6. It is concluded that 5,6-dihydroxytryptamine and its diacetyl derivative stimulate postsynaptic 5-HT receptors, but that their effect is weaker than that of 5-HT.

Airway Resistance↗
PubMed1994

Chlormethiazole and dizocilpine block the behavioural, but not the neurotoxic effects of 5,7-dihydroxytryptamine in mice.

Intracerebroventricular administration to mice of 5,7-dihydroxytryptamine at a dose of 300 micrograms resulted in convulsive behaviour and death (latency 7.6 +/- 1.7 min.). Pretreatment with dizocilpine or chlormethiazole resulted in a dose dependent inhibition of the convulsive behaviour. A dose of dizocilpine of 0.12 mumol/kg or chlormethiazole at a dose of 150 mumol/kg prevented seizures for 30 min. Injection of 5,7-dihydroxytryptamine (75 micrograms, intracerebroventricularly) produced an approximate 50% neurotoxic loss of cerebral 5-hydroxytryptamine (5-HT) and its metabolite 5-hydroxyindole acetic acid (5-HIAA) 8 days later. This loss was not prevented by administration of either dizocilpine (4.5 mumol/kg intraperitoneally) or chlormethiazole (300 mumol/kg intraperitoneally) given 5 min. before and 55 min. after the 5,7-dihydroxytryptamine injection. It is proposed that chlormethiazole and dizocilpine may protect against 5,7-dihydroxytryptamine-induced seizures because of their anticonvulsant activity, but that they do not prevent the neurotoxic effects of the compound. The data also suggest that the neurotoxic effects of substituted amphetamines such as 3,4-methylene dioxymethamphetamine (MDMA or Ecstasy) do not result from the formation of a 5,7-dihydroxytryptamine like compound.

5,7-Dihydroxytryptamine↗
PubMed1976

Cardiovascular toxicity of dihydroxytryptamines.

A comparison of the acute toxicity and a histological examination of the toxic effects in mouse of 4,7-; 5,6-; 5,7- and 6,7-dihydroxytryptamines and related compounds are present. A time and dose dependent induction of subepicardial lesions by 5,6-dihydroxytryptamine is demonstrated. The development of ischemic necrosis of the vaculature of the tail following 6,7-dihydroxytryptamine is described. The toxic effects of these tryptamines are discussed with regard to the phenomena of specific neurodegeneration induced by 5,6- and 5,7-dihydroxytryptamines.

5,6-Dihydroxytryptamine↗
PubMed1987

Effect of intranigral administration of 6-hydroxydopamine and 5,7-dihydroxytryptamine on rat brain tryptamine.

Earlier experiments have shown that unilateral electrolytic lesions of the substantia nigra result in significant reductions in the rate of accumulation of rat striatal tryptamine. For elucidation of the type of neuronal degeneration that is associated with tryptamine depletion, the effects of intranigral injections of 6-hydroxydopamine or 5,7-dihydroxytryptamine, which would affect, respectively, dopamine- or indoleamine-containing neurons, have been assessed. Nigral 6-hydroxydopamine lesions resulted in an ipsilateral reduction in the rate of accumulation of striatal tryptamine, but no changes were observed after nigral injections of 5,7-dihydroxytryptamine. The present results suggest that decreases in the pargyline-induced accumulation of striatal tryptamine may be associated with lesions of the nigral dopamine-containing cell bodies. Alternatively, there may exist specific tryptamine-containing neurons that are damaged by 6-hydroxytryptamine and unaffected by 5,7-dihydroxytryptamine.

5,7-Dihydroxytryptamine↗
PubMed1996

Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats.

Possible adaptive changes of the recently cloned serotonin 5-HT6 receptor after the selective lesion of serotoninergic neurons by an intracerebral administration of 5,7-dihydroxytryptamine were investigated using competitive RT-PCR (reverse transcription followed by polymerase chain reaction) for the measurement of 5-HT6-mRNA in various areas of the rat central nervous system. In control rats, 5-HT6-mRNA was the most abundant in the nucleus accumbens, followed by the olfactory tubercle and the striatum. High levels of 5-HT6-mRNA were also found in the hypothalamus and the hippocampus, whereas the cerebral cortex, the substantia nigra, and the spinal cord contained moderate levels of the transcript. Low but easily quantifiable levels of 5-HT6-mRNA were measured in the ventral tegmental area, the anterior raphe area, and the cerebellum. In addition, moderate to low levels of this mRNA were also found in dorsal root ganglia and the pituitary gland. Three weeks after the microinfusion of 5,7-dihydroxytryptamine into the anteroventral vicinity of the dorsal raphe nucleus in nomifensine-pretreated rats, the levels of serotonin transporter-mRNA were reduced by 90% in the anterior raphe area, as expected of the extensive lesion of serotoninergic neurons. In contrast, quantitative determinations of the 5-HT6-mRNA in this area as well as in the nucleus accumbens, the striatum, and the hippocampus indicated that its levels were not significantly different in 5,7-dihydroxytryptamine-treated rats and in controls. These data showed that the 5-HT6 receptor: 1) is not an autoreceptor, and 2) exhibits probably no up regulation in postsynaptic target cells after the selective degeneration of serotoninergic projections.

5,7-Dihydroxytryptamine↗
PubMed1996

Developmental alterations in 5-hydroxytryptamine concentration and turnover after treatment of neonatal rats with 5,7-dihydroxytryptamine.

Early disruption of the serotonin neurotransmitter system may have important consequences for normal neuro-physiological development. In order to further understand the neurochemical changes which occur after early insults to the system, intracerebroventricular injections of the serotonin-selective toxin, 5,7-dihydroxytryptamine were given to Sprague-Dawley rat pups on day 3 of life. Serotonin and 5-hydroxyindoleacetic acid concentration in cortex, striatum, hippocampus, and brainstem were measured after 4, 8, and 12 weeks. In controls, serotonin concentration in the striatum and cortex increased from 4 to 12 weeks, while it reached adult levels by 4 weeks in the hippocampus. 5-Hydroxyindoleacetic acid increased in cortex and hippocampus and was unchanged after 4 weeks in the striatum. An index of serotonin turnover (5-hydroxyindoleacetic acid/serotonin) decreased in striatum and cortex, but increased in the hippocampus over time. 5,7-Dihydroxytryptamine treatment induced permanent decreases in serotonin and 5-hydroxyindoleacetic acid concentration in all three forebrain regions, but had no region- and time-specific effects on serotonin turnover. In the brainstem of controls, serotonin concentration increased from 4 to 12 weeks, while 5-hydroxyindoleacetic acid concentration was unchanged, resulting in decreasing turnover. After 5,7-dihydroxytryptamine treatment, the brainstem did not show depletions of serotonin concentration in spite of significant serotonin neuronal loss, suggesting that compensatory mechanisms in remaining neurons may permit increased serotonin production. Regional and time-dependent responses to serotonin depletion may have functional implications for the developmental regulation of serotonin transmission after early insults to this neurotransmitter system.

5,7-Dihydroxytryptamine↗
PubMed1992

Peroxidase-promoted oxidation and peroxidation of the serotonergic neurotoxin 5,7-dihydroxytryptamine. A new pathway for its metabolic degradation.

Spectral data provide the first evidence that lactoperoxidase, a model enzyme for most mammalian peroxidases, catalyzed the one-electron oxidation and/or peroxidation of 5,7-dihydroxytryptamine. This process correlates with the production of superoxide radicals as is evident from the observed inhibitory effect of superoxide dismutase on product formation. 5,7-Dihydroxytryptamine is a classical peroxidase-oxidase substrate acting as a one-electron donor for enzyme compounds I, II and III. The one-electron peroxidatic oxidation of this serotonergic neurotoxin, responsible for the selective degeneration of central (5-hydroxytryptamine) neurons, is a fast process requiring measurement on the ms time scale. Attention is drawn to the biochemical and toxicological implications, because this fast reaction results in formation of known cell damaging species: free radicals, superoxide radicals and quinoidal products probably involved in the toxic action of 5,7-dihydroxytryptamine.

5,7-Dihydroxytryptamine↗